According to Zhou et al.,36 the rate of HER2 overexpression (IHC2+ and 3+) among the Chinese UC population stands at 44%, with HER2‐positive patients constituting 51% of bladder cancer cases and 38% of upper tract UC (UTUC) cases. The gene discussed is ERBB2; the disease is renal pelvis/ureter urothelial carcinoma.